Swiss National Bank Has $1.28 Million Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

Swiss National Bank cut its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) by 5.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 174,700 shares of the company’s stock after selling 10,500 shares during the period. Swiss National Bank owned approximately 0.13% of Vir Biotechnology worth $1,282,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in VIR. Rhumbline Advisers increased its position in Vir Biotechnology by 0.5% in the 4th quarter. Rhumbline Advisers now owns 236,681 shares of the company’s stock worth $1,737,000 after buying an additional 1,288 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Vir Biotechnology by 31.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,999 shares in the last quarter. Public Sector Pension Investment Board grew its stake in shares of Vir Biotechnology by 1.4% in the 3rd quarter. Public Sector Pension Investment Board now owns 194,208 shares of the company’s stock valued at $1,455,000 after purchasing an additional 2,600 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Vir Biotechnology by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 29,202 shares of the company’s stock worth $214,000 after acquiring an additional 2,922 shares in the last quarter. Finally, KBC Group NV increased its position in shares of Vir Biotechnology by 136.5% during the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock worth $66,000 after purchasing an additional 5,177 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total transaction of $137,219.20. Following the transaction, the director now owns 1,312,391 shares in the company, valued at $16,431,135.32. This trade represents a 0.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Verneuil Vanina De sold 7,373 shares of the business’s stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the sale, the executive vice president now directly owns 79,460 shares of the company’s stock, valued at $726,264.40. This represents a 8.49 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,859 shares of company stock worth $326,458. Company insiders own 15.60% of the company’s stock.

Vir Biotechnology Price Performance

Shares of NASDAQ VIR opened at $6.70 on Friday. Vir Biotechnology, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $14.45. The stock has a market capitalization of $918.86 million, a price-to-earnings ratio of -1.71 and a beta of 1.17. The business has a 50-day moving average of $8.80 and a 200-day moving average of $8.35.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. The firm had revenue of $12.37 million during the quarter, compared to analysts’ expectations of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. On average, sell-side analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Barclays lifted their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Leerink Partners upped their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. JPMorgan Chase & Co. increased their price target on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research report on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a report on Friday, February 28th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.67.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).